A pilot randomized study for optimal red cell transfusion in acute myeloid leukemia patients with intensive chemotherapy.

ABSTRACT:

Background

Although blood transfusion is fundamental throughout the course of hematologic malignancies, acute myeloid leukemia (AML) patients requiring intensive chemotherapy are left at the edges of patient blood management programs because current guidelines do not have established recommendations for red blood cell (RBC) transfusion threshold in patients treated for hematological disorders with anemia and accompanied severe thrombocytopenia. To provide answers for the trigger and doses of ideal RBC transfusion in such situation, we conducted this prospective randomized trial.

Materials and methods

Newly diagnosed non-acute promyelocytic AML patients undergoing chemotherapy were considered eligible for enrollment. Patients were randomized into 4 groups using a 2 by 2 facto

SUBMITTER: Byun JM 

PROVIDER: S-EPMC10645352 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature